Valbenazine

SKU: orb1300029

Description

Valbenazine

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1025504-45-3
• MW: 418.57
• Purity: 99.68%
• Formula: C₂₄H₃₈N₂O₄
• SMILES: [H][C@]12C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CCc1cc(OC)c(OC)cc21
• Target: Monoamine Transporter
• Solubility: DMSO:50 mg/mL (119.45 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.78 mM)

Bioactivity

• In Vivo:
  Valbenazine appeared to be well tolerated in adults with TD who received up to 48 weeks of treatment. In addition to long-term efficacy results, Suggest that valbenazine may be appropriate for the long-term management of TD regardless of underlying psychiatric diagnosis (SCHZ disorder or mood disorder).
• Animal Research:
  The pooled long-term exposure (LTE) population included valbenazine-treated subjects from 3 studies: KINECT; KINECT 3; KINECT4. Safety assessments included adverse events (AEs), laboratory tests, vital signs, electrocardiograms (ECGs), and extrapyramidal symptom (EPS) scales. Psychiatric stability was monitored using the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) (SCHZ subgroup), as well as the Montgomery- sberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) (mood subgroup). All data were analyzed descriptively.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

MonoamineTransporter, monoamine, Monoamine Transporter, Inhibitor, Huntington, inhibit, NBI 98854, NBI98854, NBI-98854, disease, transporter, Valbenazine, vesicular, VMAT2

Compound Identifiers

PubChem CID

24795069